Based on the key indicators related to Cns Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Cns Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April. At this time, Cns Pharmaceuticals' Total Liabilities is relatively stable compared to the past year. As of 03/22/2025, Short and Long Term Debt is likely to grow to about 362.4 K, while Net Tangible Assets are likely to drop slightly above 6 M. Key indicators impacting Cns Pharmaceuticals' financial strength include:
Investors should never underestimate Cns Pharmaceuticals' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Cns Pharmaceuticals' cash flow, debt, and profitability to make informed and accurate decisions about investing in Cns Pharmaceuticals.
Net Income
(16.12 Million)
Cns
Select Account or Indicator
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Cash Ratio
Cash Conversion Cycle
Cash Flow Coverage Ratios
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Change In Cash
Net Borrowings
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Capital Expenditures
Total Cash From Operating Activities
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Non Cash Items
Issuance Of Capital Stock
Investments
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Surpluse
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Short Long Term Debt
Total Current Assets
Net Working Capital
Short Term Debt
Common Stock
Other Assets
Capital Stock
Property Plant And Equipment Net
Property Plant Equipment
Interest Income
Interest Expense
Selling General Administrative
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Net Interest Income
Depreciation And Amortization
Other Operating Expenses
Ebitda
Income Tax Expense
Gross Profit
Cost Of Revenue
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Cns Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Cns Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Cns Pharmaceuticals' assets may result in an increase in income on the income statement.
Cns Pharmaceuticals competes with ZyVersa Therapeutics, Immix Biopharma, Sonnet Biotherapeutics, Enveric Biosciences, and Elevation Oncology. CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company was incorporated in 2017 and is based in Houston, Texas. Cns Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Cns Pharmaceuticals' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Cns Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Cns Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cns Pharmaceuticals competition to find correlations between indicators driving Cns Pharmaceuticals's intrinsic value. More Info.
Cns Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Cns Pharmaceuticals' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Cns Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Cns Pharmaceuticals Systematic Risk
Cns Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Cns Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Cns Pharmaceuticals correlated with the market. If Beta is less than 0 Cns Pharmaceuticals generally moves in the opposite direction as compared to the market. If Cns Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Cns Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Cns Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Cns Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Cns Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cns Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Cns Pharmaceuticals growth as a starting point in their analysis.
Cns Pharmaceuticals March 22, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Cns Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cns Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cns Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Cns Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cns Pharmaceuticals's daily price indicators and compare them against related drivers.
When running Cns Pharmaceuticals' price analysis, check to measure Cns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cns Pharmaceuticals is operating at the current time. Most of Cns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.